复发性妊娠丢失中「子宫因素」的重要性:基于三维经阴道超声筛查女性的回顾性队列研究
该回顾性队列纳入442例至少两次早孕期自然妊娠丢失且病因不明的女性,由专家独立复核三维经阴道超声图像,按ASRM 2021、ESHRE/ESGE与CUME标准诊断先天性子宫异常,并按FIGO与MUSA标准诊断获得性子宫异常。部分纵隔子宫的患病率随诊断标准不同为7%至14%,T形子宫为3%或4%,子宫腺肌病为23%,至少一个FIGO 0、1或2型肌瘤为4%,至少一个子宫内膜息肉为4%。
要点
- 部分纵隔子宫患病率依ESHRE/ESGE、ASRM 2021、CUME标准分别为14%、7%、11%。
- T形子宫按ESHRE/ESGE标准为4%,按CUME标准为3%;边缘型T形子宫为4%。
- 子宫腺肌病患病率为23%,在原发性复发性妊娠丢失及≥3次妊娠丢失者中更常见。
核心结论
- 复发性妊娠丢失女性中先天性子宫异常的患病率随所用分类系统而变化。
- 子宫腺肌病似乎与更严重的复发性妊娠丢失形式相关。
- 本研究估计的患病率及所用诊断标准的可重复性为前瞻性研究的设计与样本量计算提供了依据。
研究设计与样本
- 这是一项回顾性队列研究,纳入442例至少两次早孕期自然妊娠丢失(即非存活宫内妊娠)的女性,她们于2020年7月至2023年7月期间就诊于两家大学医院的妇产科。
- 纳入条件包括年龄25至42岁、无相关合并症、无不孕、从未接受辅助生殖技术、夫妇双方复发性妊娠丢失全面诊断检查阴性、且从未接受子宫成形术、肌瘤剔除术、子宫肌瘤微创治疗或子宫腺肌病切除术。
- 由专家超声医师独立重新分析所有纳入患者存储的二维和三维经阴道超声图像。
主要发现
- 部分纵隔子宫按ESHRE/ESGE、ASRM 2021和CUME标准分别诊断60例(14%;95%CI:11-17%)、29例(7%;95%CI:5-9%)和47例(11%;95%CI:8-14%)。
- T形子宫按ESHRE/ESGE标准诊断19例(4%;95%CI:3-7%),按CUME标准诊断13例(3%;95%CI:2-5%);边缘型T形子宫(满足CUME T形子宫三条标准中的两条)见于16例(4%;95%CI:2-6%)。
- 至少一个FIGO 0、1或2型肌瘤见于4%的纳入对象(95%CI:3-6%);至少一个子宫内膜息肉见于4%的入组女性(95%CI:3-7%)。
- 子宫腺肌病检出100例(23%;95%CI:19-27%),在原发性复发性妊娠丢失女性及三次或以上妊娠丢失女性中显著更常见。
关键数值与推荐
- 先天性子宫异常按美国生殖医学学会(ASRM)2021、ESHRE/欧洲妇科内镜学会(ESGE)和专家先天性子宫畸形(CUME)标准报告。
- 获得性子宫异常按国际妇产科联盟(FIGO)和子宫形态超声评估(MUSA)标准报告。
- ESHRE与皇家学院(Royal College)复发性妊娠丢失指南推荐采用三维经阴道超声评估「子宫因素」。
临床怎么用
- 超声报告应始终写明子宫异常的名称以及所采用的分类与诊断标准。
- ESHRE与皇家学院(Royal College)复发性妊娠丢失指南推荐采用三维经阴道超声评估「子宫因素」。
局限性
- 缺乏对照组,无法探究先天性与获得性子宫异常和复发性妊娠丢失之间是否存在关联。
- 三维超声检出的先天性与获得性子宫异常的存在与否均未通过宫腔镜确认。
- 本研究结果不可避免地受所采用分类系统固有局限性的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What is the prevalence of congenital and acquired anomalies of the uterus in women with recurrent pregnancy loss (RPL) of unknown etiology examined using 3D transvaginal ultrasound (US)? SUMMARY ANSWER: Depending on the adopted diagnostic criteria, the prevalence of partial septate uterus varies between 7% and 14% and a T-shaped uterus is 3% or 4%, while adenomyosis is 23%, at least one of type 0, type 1 or type 2 myoma is 4%, and at least one endometrial polyp is 4%. WHAT IS KNOWN ALREADY: ESHRE and the Royal College of Obstetricians and Gynaecologists guidelines on RPL recommend the adoption of the 3D transvaginal US to evaluate the 'uterine factor'. Nevertheless, there are no published studies reporting the prevalence of both congenital and acquired uterine anomalies as assessed by 3D transvaginal US and diagnosed according to the criteria proposed by the most authoritative panels of experts in a cohort of women with RPL. STUDY DESIGN, SIZE, DURATION: This was a retrospective cohort study including 442 women with at least two previous first-trimester spontaneous pregnancy losses (i.e. non-viable intrauterine pregnancies), who referred to the obstetrics and gynecology unit of two university hospitals between July 2020 and July 2023. PARTICIPANTS/MATERIALS, SETTING, METHODS: Records of eligible women were reviewed. Women could be included in the study if: they were between 25 and 42 years old; they had no relevant comorbidities; they were not affected by infertility, and they had never undergone ART; they and their partner tested negative to a comprehensive RPL diagnostic work-up; and they had never undergone metroplasty, myomectomy, minimally invasive treatments for uterine fibroids or adenomyomectomy. Expert sonographers independently re-analyzed the stored 2- and 3D transvaginal US images of all included patients. Congenital uterine anomalies (CUAs) were reported according to the American Society for Reproductive Medicine (ASRM) 2021, the ESHRE/European Society for Gynaecological Endoscopy (ESGE) and the Congenital Uterine Malformation by Experts (CUME) criteria. Acquired uterine anomalies were reported according to the International Federation of Gynecology and Obstetrics (FIGO) and the Morphological Uterus Sonographic Assessment (MUSA) criteria. MAIN RESULTS AND THE ROLE OF CHANCE: The partial septate uterus was diagnosed in 60 (14%; 95% CI: 11-17%), 29 (7%; 95% CI: 5-9%), and 47 (11%; 95% CI: 8-14%) subjects, according to the ESHRE/ESGE, the ASRM 2021, and the CUME criteria, respectively. The T-shaped uterus was diagnosed in 19 women (4%; 95% CI: 3-7%) according to the ESHRE/ESGE criteria and in 13 women (3%; 95% CI: 2-5%) according to the CUME criteria. The borderline T-shaped uterus (diagnosed when two out of three CUME criteria for T-shaped uterus were met) was observed in 16 women (4%; 95% CI: 2-6%). At least one of FIGO type 0, type 1, or type 2 myoma was detected in 4% of included subjects (95% CI: 3-6%). Adenomyosis was detected in 100 women (23%; 95% CI: 19-27%) and was significantly more prevalent in women with primary RPL and in those with three or more pregnancy losses. At least one endometrial polyp was detected in 4% of enrolled women (95% CI: 3-7%). LIMITATIONS, REASONS FOR CAUTION: The absence of a control group prevented us from investigating the presence of an association between both congenital and acquired uterine anomalies and RPL. Second, the presence as well as the absence of both congenital and acquired uterine anomalies detected by 3D US was not confirmed by hysteroscopy. Finally, the results of the present study inevitably suffer from the intrinsic limitations of the adopted classification systems. WIDER IMPLICATIONS OF THE FINDINGS: The prevalence of CUAs in women with RPL varies depending on the classification system used. For reasons of clarity, the US reports should always state the name of the uterine anomaly as well as the adopted classification and diagnostic criteria. Adenomyosis seems to be associated with more severe forms of RPL. The prevalence rates estimated by our study as well as the replicability of the adopted diagnostic criteria provide a basis for the design and sample size calculation of prospective studies. STUDY FUNDING/COMPETING INTEREST(S): No specific funding was used. The authors have no conflicts of interest to declare. TRIAL REGISTRATION NUMBER: N/A.
引用
- Busnelli A, Barbaro G, Pozzati F, et al. The importance of the 'uterine factor' in recurrent pregnancy loss: a retrospective cohort study on women screened through 3D transvaginal ultrasound. Hum Reprod. 2024. PMID: 38964365. doi:10.1093/humrep/deae148
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。